1-5 of 5
Juan Carlos Varela
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

Jessica Liegel, Giulia Cheloni, Georges Chedid, Genevieve Gerhard, Dimitra Karagkouni, Richard Stone, Robert J. Soiffer, Lina Bisharat, Samprity Ankita, Isabella Saldarriaga, Emma K Logan, Michele Narcis, Jennifer Tichon, Yiwen Liu, Malgorzata McMasters, Juan Carlos Varela, Hassan El Banna, Vincent T. Ho, Rizwan Romee, Donna S. Neuberg, Kathrine S Rallis, Sophia Adamia, Benjamin L. Ebert, Donald Kufe, Ioannis Vlachos, David Avigan, Jacalyn Rosenblatt
Journal: Blood
Blood (2023) 142 (Supplement 1): 772.
https://doi.org/10.1182/blood-2023-190832
Published: 2023
Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar
Journal: Blood
Blood (2022) 140 (Supplement 1): 10416–10418.
https://doi.org/10.1182/blood-2022-159595
Published: 2022
Journal Articles

Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant

Juan Carlos Varela, Sojung Kim, Robert D Knight, Emily Lu, Ruipeng Wang, Monzr M. Al Malki
Journal: Blood
Blood (2022) 140 (Supplement 1): 4521.
https://doi.org/10.1182/blood-2022-170266
Published: 2022
Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 832.
https://doi.org/10.1182/blood-2019-127345
Published: 2019
Journal Articles

Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia

Shahram Mori, MD PhD, Nahir Rivera, PharmD BCOP, Mohammed Wazir, MD, Rushang D. Patel, MD PhD, Juan Carlos Varela, MD PhD, Xiang Zhu, MAS, Jason Balls, PAC, Tori Smith, ARNP, Steven C. Goldstein, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3988.
https://doi.org/10.1182/blood-2018-99-120285
Published: 2018